investor login

contact

team

dedicated funds

news

 portfolio

Developer of a system to enhance embolic cerebral protection, enabling interventionalists to reduce the frequency of embolic strokes during cardiovascular procedures.

 

Acquired by Edwards Lifesciences (NYSE: EW) in March 2011.

Exited, HVP III, Med Tech

back to portfolio

contact

© hatteras venture partners | all rights reserved | terms + privacy | site credit

 team

 portfolio

news

home

Hatteras Venture Partners is a venture capital firm that builds transformational companies in areas of health innovation.

dedicated funds

contact

 team

dedicated funds

news

home

 portfolio